| Literature DB >> 35774735 |
Elenjickal Elias John1, Sanjeet Roy2, Selvin Sundar Raj Mani1, Jeethu Joseph Eapen1, Utkarash Mishra1, Santosh Varughese1.
Abstract
Dual anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) characterized by the presence of both anti-proteinase-3 (PR3-ANCA) and anti-myeloperoxidase (MPO-ANCA) antibodies is a rare clinical entity. Only few cases have been reported previously, most of which were associated with infections, drugs, autoimmune diseases and malignancies. Herein, we describe a young woman who presented with rapidly progressive glomerulonephritis with hypocomplementemia and markedly elevated anti-PR3 and anti-MPO titres. Meticulous work-up ruled out all possible secondary causes. Renal biopsy showed the presence of focal fibrocellular crescents with focal mesangial hypercellularity. Immunofluorescence and electron microscopy showed pauci-immune deposits. The patient was treated with an induction regimen comprising oral prednisolone and cyclophosphamide. She attained both clinical and serological remission at 3 months and is currently on an azathioprine-based maintenance regimen. We have extensively reviewed all previous cases of dual AAV and have formulated an approach to diagnose and treat this rare entity. LEARNING POINTS: Dual anti-neutrophil cytoplasmic antibody-associated vasculitis characterized by both PR3-ANCA and MPO-ANCA antibodies is a rare clinical entity.Prior to treating with immunosuppression, we need to rule out secondary aetiologies such as drugs, certain infections, autoimmune diseases and haematological malignancies.Atypical presentations such as hypocomplementemia, other serological abnormalities like positive ANA, cryoglobulins, anti-histone antibody and histology showing mesangial hypercellularity, interstitial inflammation and lack of pauci-immunity, may create a diagnostic dilemma. © EFIM 2022.Entities:
Keywords: ANCA-associated vasculitis; anti-myeloperoxidase; anti-proteinase-3; crescents; hypocomplementemia
Year: 2022 PMID: 35774735 PMCID: PMC9239025 DOI: 10.12890/2022_003365
Source DB: PubMed Journal: Eur J Case Rep Intern Med ISSN: 2284-2594
Causes of dual anti-neutrophil cytoplasmic antibody-associated vasculitis
| Aetiology | Prevalence of dual AAV (%) | Salient clinical features |
|---|---|---|
|
| ||
| Hydralazine | 39 | More than 1 year of drug intake, anti-MPO titres>anti-PR3 titres, anti-histone antibody (98%), ANA (89%), hypocomplementemia (58%), dsDNA (45%), mesangial hypercellularity (30%), Berden class: focal (50%), immune deposits on IF (20%), electron dense deposits (62%) |
| Cocaine adulterated with Levamisole | 50 | Necrotizing skin lesions, CIMDL, HLE ANCA, ANA (82%), hypocomplementemia (63%), LA (66%) |
| Propylthiouracil | 10–11 | Young females, less organ involvement, lower BVAS, less proteinuria, higher eGFR, histology: fewer crescents, interstitial inflammation and IFTA, good renal prognosis |
| Cimetidine | Case report | Severe interstitial mononuclear cell infiltration |
|
| ||
| Sub-acute bacterial endocarditis | 35 | Younger age, hepatosplenomegaly, new heart murmurs (SABE), hypocomplementemia, anti-PR3 titres>anti-MPO titres, cryoglobulin (50%), lower relapse rates |
|
| ||
| SLE | Case report | ANA, dsDNA, relapse |
| MCTD | Case report | ANA, anti U1-RNP antibody |
| HSP | Case report | Elevated serum IgA |
| Haematological malignancy | Case report | |
| Idiopathic dual AAV | Current case | Young age, hypocomplementemia, anti-PR3 titres=anti-MPO titres, mesangial hypercellularity |
AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; ANA, anti-nuclear antibody; BVAS, Birmingham Vasculitis Activity score; CIMDL, cocaine-induced midline destructive lesions; CoNS, coagulase negative staphylococcus; dsDNA, double-stranded DNA; eGFR, estimated glomerular filtration rate; HLE, human leucocyte elastase; HSP, Henoch-Schonlein purpura; IF, immunofluorescence; IFTA, interstitial fibrosis and tubular atrophy; LA, lupus anticoagulant; MCTD, mixed connective tissue disease; MPO, myeloperoxidase; PR3, proteinase 3; SABE, sub-acute bacterial endocarditis; SLE, systemic lupus erythematosus.
Figure 1Renal biopsy findings of the current case of dual ANCA-associated vasculitis (1A) Fibrocellular crescent occluding capillary loop with interstitial mononuclear cell infiltration (haematoxylin and eosin stain; original magnification ×200). (1B) Glomerulus with congested loops and mild mesangial hypercellularity (periodic acid-Schiff stain; original magnification ×200). (1C) Glomeruli demonstrating mesangial ill-defined electron-dense deposits (bold black arrows) (transmission electron microscope; original magnification ×4200). (1D) Segment of glomeruli displaying a rare para-mesangial notch hump-like electron-dense deposit (marked with bold black arrow). Overlying podocytes showed marked foot process effacement. (transmission electron microscope; original magnification, ×4200)
Comparison of previously reported cases of dual anti-neutrophil cytoplasmic antibody associated vasculitis with the current case
| Author | Meisels et al.[ | Kim et al.[ | Guardiola et al.[ | Chou et al.[ | Amaro et al.[ | Ueda et al.[ | Tiliakos et al.[ | Sakalli et al.[ | Murakami et al.[ | Boyle et al.[ | John et al. (current case) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Country | Boston | South Korea | Spain | Australia | Spain | Japan | Pennsylvania, USA | Turkey | Japan | Australia | India | |
| Duration of study | 1997 | 1997–2016 | 1999 | 2003–2013 | 2004 | 2005 | 2008 | 2011 | 2012 | 2020 | 2022 | |
| Total patients with dual AAV | 1 | 8 | 1 | 15 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | |
| Age (years) | 50 | 68.5 (47–76) (median) | 77 | – | 60 | 75 | 50 | 64 | 12 | 38 | 70 | 30 |
| Sex | Male | 1.6:1 (M:F) | Female | – | Male | Male | Male | Male | Female | Female | Female | Female |
|
|
|
| ||||||||||
| Constitutional symptoms | No | 0 | Yes | 0 | No | Yes | Yes | No | No | Yes | No | No |
| Upper respiratory tract | No | 75 | Yes | 66 | No | No | Yes | No | No | No | No | No |
| Lower respiratory tract | No | 75 | Yes | 40 | No | No | No | No | No | Yes | Yes | No |
| Kidney | Yes | 100 | Yes | 26.6 | Yes | Yes | Yes | No | No | No | Yes | Yes |
| CNS | No | 62.5 | Yes | 13.3 | No | No | Yes | Yes | Moyamoya | Yes | No | No |
| CVS | No | 25 | No | 0 | No | No | No | No | No | No | No | No |
| GIT | No | 0 | No | 0 | No | No | Yes | Yes | No | No | No | No |
| Skin | No | 0 | Yes | 0 | Yes | Yes | No | No | Yes | Yes | Yes | No |
| Joints | No | 0 | No | 0 | Yes | No | Yes | No | No | Yes | Yes | No |
| Eye | No | 0 | No | 0 | No | No | No | No | Retinal thrombosis | No | No | No |
| Aetiological diagnosis | (%) | (%) | ||||||||||
| GPA | – | 25 | – | 0 | – | – | – | – | – | – | – | – |
| MPA | – | 75 | – | 13.3 | – | – | – | – | – | – | – | – |
| EGPA | – | 0 | EGPA+GCA | 6.6 | – | – | – | – | – | – | – | – |
| Renal limited vasculitis | – | 0 | – | 6.6 | – | – | – | – | – | – | – | Yes |
| Drug-induced AAV | – | 0 | – | 6.6 | – | Cimetidine | – | – | – | – | – | – |
| Infection-induced AAV | – | 0 | – | 46.6 | – | – | IE | IE | – | – | – | – |
| Autoimmune disease | – | 0 | – | 20 | – | – | – | – | Moyamoya | MCTD | SLE | – |
| Malignancy | – | 0 | – | 0 | – | – | – | – | – | – | – | – |
| Glomerulonephritis | MN | 0 | – | 0 | HSP | – | – | – | – | – | – | – |
| Hypertension | – | – | – | – | No | Yes | Yes | Yes | – | No | No | Yes |
| Kidney function at presentation | Median (range) | |||||||||||
| Creatinine (mg/dl) | 6.9 | 4.3 (0.7–13.5) | 1.24 | – | Normal | 2.9 | – | – | – | 0.5 | 2.91 | 6.87 |
| eGFR (ml/min/1.73m2) | - | 16.5 (3.4–29) | 32.57 | _ | Normal | 44 | _ | _ | 110 | – | – | 7.3 |
| Urine microscopy (%) | ||||||||||||
| Proteinuria | Yes | 100 | Yes | – | Yes | No | Yes | No | No | Yes | Yes | Yes |
| Microhaematuria | Yes | 100 | Yes | _ | Yes | No | Yes | No | No | Yes | Yes | Yes |
| 24-hour urine protein (g/day) | – | – | 0.8 | – | 3.14 | – | – | – | – | – | – | 1.6 |
| Albumin (g/dl) | _ | – | – | – | – | 3.2 | – | – | – | 2.8 | – | 2.8 |
| Haemoglobin (g/dl) | – | – | 8.8 | – | 14.2 | 12.4 | 12 | 11.2 | – | 11.6 | 10.1 | 5.1 |
| Total leucocyte count (cells/mm2) | – | – | 13,780 | – | 8400 | 4300 | 9300 | 8000 | – | 14,100 | – | 11,100 |
| C-reactive protein | – | – | – | – | Elevated | – | – | – | Normal | Elevated | Elevated | Elevated |
| ANCA antibody titre (U/ml) at diagnosis | ||||||||||||
| PR3-ANCA | – | – | 64 | – | 37 | 246 | 11 | 24 | – | 80.3 | >100 | >200 |
| MPO-ANCA | – | – | 34 | – | 40 | 318 | 17 | 16 | – | 31.3 | >100 | >200 |
| Serological profile | ||||||||||||
| Hepatitis B | – | – | – | – | Negative | Negative | Negative | Negative | Negative | – | Negative | |
| Hepatitis C | – | – | – | – | Negative | Negative | Negative | Negative | Negative | – | Negative | |
| ANA | Negative | – | Positive | – | Negative | Negative | Negative | Positive | Positive | Positive | Negative | |
| dsDNA | Negative | – | – | – | Negative | – | Negative | Negative | Negative | Positive | Negative | |
| C3 | – | – | – | – | Normal | Normal | – | Normal | Normal | Normal | Low | |
| C4 | – | – | – | – | Normal | Normal | – | Normal | Normal | Normal | Normal | |
| Cryoglobulins | – | – | – | – | Negative | – | – | – | – | – | Negative | |
| Anti cardiolipin Ab | – | – | Positive | – | – | – | – | Positive | – | – | Negative | |
| Anti | – | – | – | – | – | – | – | – | – | – | Negative | |
| Lupus anticoagulant | – | – | – | – | – | – | – | Negative | – | – | Negative | |
| Anti histone antibody | – | – | – | – | – | – | – | – | – | – | Negative | |
| Anti U1-RNP antibody | – | – | – | – | – | – | – | – | – | – | Negative | |
| Anti GBM antibody | – | – | – | – | – | Negative | – | – | Positive | – | Negative | |
| Renal histology | ||||||||||||
| Berden’s classification | Crescent | ND | Focal | ND | Focal | Focal | ND | ND | ND | Mixed | Focal | |
| Immunofluorescence | Linear IgG and granular IgA in capillary loops | ND | - | ND | IgA deposits in mesangial and capillary wall | Pauci-immune | ND | ND | ND | Pauci-immune | Pauci-immune | |
| Electron microscopy | Sub-epithelial deposits | ND | - | ND | - | No deposits | ND | ND | ND | Focal deposits | Focal deposits | |
| Immunosuppression | ||||||||||||
| Induction therapy | Pred + oral CP + Plex | Pred | Pred | Nil | Pred | Pred | Pred + IV CP | Pred + Aza | Pred + IV CP | Pred + oral CP | ||
| Maintenance therapy | – | Pred | - | Nil | Nil | Nil | Pred | - | MMF, Ritux | Aza | ||
| Outcomes (%) | ||||||||||||
| Remission | Yes | 50% | Yes | – | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Relapse | No | 25% | No | – | No | No | No | No | No | No | No | No |
| Death | No | – | No | 33.3% | No | No | No | No | No | No | No | No |
| ANCA titres at last visit | Negative | – | – | – | Negative | Negative | Neg | Neg | Negative | Persistent | Negative | Negative |
AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; Ab, Antibody; ANA, anti-nuclear antibody; Aza, azathioprine; CNS, central nervous system; CP, cyclophosphamide; CVS, cerebrovascular system; dsDNA, double-stranded DNA; EGPA, eosinophilic granulomatosis with polyangiitis; GBM, glomerular basement membrane; GCA, giant cell arteritis; GIT, gastrointestinal tract; HSP, Henoch-Schonlein purpura; IE, infective endocarditis; MCT, mixed connective tissue disease; MN, membranous nephropathy; MPO, myeloperoxidase; ND, not done; PR3, proteinase 3; Pre, prednisolone; Plex, plasmapheresis; Ritux, rituximab; RNP, ribonucleoprotein; SLE, systemic lupus erythematosus.